v3.26.3
Description of Business and Significant Accounting Policies - Additional Information (Detail)
€ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2023
Jan. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Segment
Sep. 30, 2025
USD ($)
Sep. 30, 2026
EUR (€)
Dec. 31, 2025
USD ($)
Jul. 01, 2013
USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                    
Percentage of future royalties           1.00%        
Number of operating segment | Segment           1        
Number of reportable segment | Segment           1        
Revenue recognized related to milestone           $ 0        
Purchase of available-for-sale securities           43,778,000 $ 144,080,000      
Cost of goods sold       $ 11,213,000 $ 4,498,000 $ 33,130,000 12,873,000      
Loss on purchase commitments | €               € 55.2    
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]           srt:ChiefExecutiveOfficerMember, srt:ChiefFinancialOfficerMember        
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description           The key metric utilized by the CODM to assess resource allocation and performance is the Company’s segment net income, which is the same as the consolidated net income reported in the condensed consolidated statements of operations. The CODM also analyzes the Company's consolidated net income to evaluate its return on segment assets and to establish budgets and forecasts.        
Sagard                    
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                    
Percentage of royalty on future net sales 1.00%                  
Insulin                    
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                    
Loss on purchase commitments       63,700,000   $ 63,700,000     $ 66,000,000  
Tyvaso DPI                    
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                    
Percentage of royalty on net sales           10.00%        
Percentage of royalty on net revenue           10.00%        
Percentage of future royalties           9.00%        
Collaborations and services                    
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                    
Cost of revenue       12,299,000 $ 15,705,000 $ 37,393,000 $ 45,414,000      
Maximum | AFREZZA product sales                    
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                    
Sales return right following product expiration in months           12 months        
Minimum | AFREZZA product sales                    
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                    
Sales return right following product expiration in months           6 months        
Convertible Promissory Note | Thirona Bio, Inc.                    
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                    
Purchase of available-for-sale securities   $ 5,000,000 $ 3,000,000              
Milestone Rights Liability | Deerfield                    
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                    
Contingent liability for milestone payments       $ 40,000,000   $ 40,000,000        
Milestone Rights Liability | Maximum | Deerfield                    
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                    
Contingent liability for milestone payments                   $ 90,000,000